To evaluate the percentage of patients with either established cardiovascular disease (CVD), at "high risk" of developing CVD or with diabetes who are on simvastatin 40mg, with fasting LDL-C \> 2mmol/l, who are able to attain the recommended LDL-C target of \< 2mmol/l following 6 weeks treatment with either ezetimibe/simvastatin 10/40mg, atorvastatin 40mg or rosuvastatin 10mg.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
786
ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End
Fasting LDL-C was the primary efficacy variable. The primary efficacy analysis was based on the proportion of patients achieving a target of \<2mmol/l in fasting LDL-C at study end.
Time frame: 6 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.